{"groups":[{"description":"Children and adolescents newly diagnosed with Philadelphia chromosome positive acute lymphocytic leukemia (Ph+ ALL) treated with standard multiagent chemotherapy and Dasatinib (either in tablets or Powder For Oral Suspension (PFOS)) at a dose of 60 mg/m2 daily.","id":"FG000","title":"Dasatinib Cohort"}],"periods":[{"dropWithdraws":[{"reasons":[{"groupId":"FG000","numSubjects":"3"}],"type":"Lack of Efficacy"},{"reasons":[{"groupId":"FG000","numSubjects":"2"}],"type":"Study Drug Toxicity"},{"reasons":[{"groupId":"FG000","numSubjects":"8"}],"type":"Adverse Event"},{"reasons":[{"groupId":"FG000","numSubjects":"4"}],"type":"Withdrawal by Subject"},{"reasons":[{"groupId":"FG000","numSubjects":"2"}],"type":"Death"},{"reasons":[{"groupId":"FG000","numSubjects":"9"}],"type":"Other reasons"}],"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"106"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"78"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"28"}],"type":"NOT COMPLETED"}],"title":"Treatment Phase"},{"dropWithdraws":[{"reasons":[{"groupId":"FG000","numSubjects":"4"}],"type":"Withdrawal by Subject"},{"reasons":[{"groupId":"FG000","numSubjects":"14"}],"type":"Death"},{"reasons":[{"groupId":"FG000","numSubjects":"7"}],"type":"Lost to Follow-up"},{"reasons":[{"groupId":"FG000","numSubjects":"70"}],"type":"Follow-up no longer required per protocol"},{"reasons":[{"groupId":"FG000","numSubjects":"5"}],"type":"Other and not reported reasons"}],"milestones":[{"achievements":[{"comment":"Some of the participants who did not completed the Treatment Phase were still moved to the Follow-up Phase","groupId":"FG000","numSubjects":"100"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"0"}],"comment":"Completed = continuing in the follow-up phase","type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"100"}],"type":"NOT COMPLETED"}],"title":"Follow-up Phase"}],"preAssignmentDetails":"106 participants were treated with dasatinib."}